Vir Biotechnology adds omitted prospectus exhibit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
424B5
Rhea-AI Filing Summary
Vir Biotechnology, Inc. (VIR) filed a supplement to its November 12, 2026 prospectus supplement solely to add the omitted Exhibit 107. The company stated that the supplement does not modify or update other information in the original filing.
Key Terms
Rule 424(b)(5)
1 terms
Rule 424(b)(5) regulatory
"pursuant to Rule 424(b)(5) under the Securities Act"
AI-generated analysis. How Rhea-AI works. Not financial advice.